Ticagrelor and central sleep apnoea: Impact of withdrawal and reintroduction

Br J Clin Pharmacol. 2019 Aug;85(8):1855-1858. doi: 10.1111/bcp.13967. Epub 2019 Jun 17.

Authors

Vincent Puel¹, Hélène Théophile², Isabelle Godard¹, Nathalie Raymond¹, Ghada Miremont-Salamé^{2

3}, Philippe Gosse⁴, Jean-Louis Pépin⁵, Antoine Pariente^{2

3}

Affiliations

¹ PEAS, Nouvelle Clinique Bel-Air, Bordeaux, France.
² Département de Pharmacologie Médicale, Centre Régional de Pharmacovigilance, CHU Bordeaux, Bordeaux, France.
³ INSERM, Bordeaux Population Health Research Center, team Pharmacoepidemiology, UMR 1219, Université de Bordeaux, Bordeaux, France.
⁴ Cardiology/Hypertension Department, University Hospital of Bordeaux, Bordeaux, France.
⁵ Institut National de la Santé et de la Recherche Médicale (INSERM), U 1042, HP2 Laboratory (Hypoxia: Pathophysiology), University Grenoble Alpes, Grenoble, France.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acute Coronary Syndrome / drug therapy*
Aged
Drug Substitution
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*
Platelet Aggregation Inhibitors / administration & dosage
Polysomnography
Prasugrel Hydrochloride / administration & dosage
Purinergic P2Y Receptor Antagonists / administration & dosage
Purinergic P2Y Receptor Antagonists / adverse effects*
Recurrence
Sleep Apnea, Central / chemically induced*
Sleep Apnea, Central / diagnosis
Ticagrelor / administration & dosage
Ticagrelor / adverse effects*

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Prasugrel Hydrochloride
Ticagrelor